Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 06, 2019 08:30 ET | Source: Vaccinex, Inc.

Vaccinex, Inc. to Present Data on Its Anti-SEMA4D Compound at the American Association for Cancer Research Annual Meeting 2019

ROCHESTER, N.Y., March 06, 2019 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics to...
January 17, 2019 08:30 ET | Source: Vaccinex, Inc.

Vaccinex, Inc. Presented Previously Disclosed Data from Ongoing Phase 1/2 Trial of VX15/2503 (Pepinemab) in Huntington’s Disease (the “SIGNAL Trial”) at Cambridge Healthtech Institute’s 18th Annual PepTalk

ROCHESTER, N.Y., Jan. 17, 2019 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics to treat...
January 16, 2019 08:30 ET | Source: Vaccinex, Inc.

Vaccinex, Inc. Announces Completion of Enrollment for Its “SIGNAL” Huntington’s Disease Trial

ROCHESTER, N.Y., Jan. 16, 2019 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) announced today that it has completed subject enrollment for the SIGNAL trial. SIGNAL is a Phase 2, multi-center,...
December 12, 2018 08:30 ET | Source: Vaccinex, Inc.

Preclinical Data on Vaccinex, Inc. Anti-SEMA4D Monoclonal Antibody in Combination with Checkpoint Inhibitors Published in Cancer Immunology Research

ROCHESTER, N.Y., Dec. 12, 2018 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics to treat...
November 15, 2018 08:30 ET | Source: Vaccinex, Inc.

Vaccinex, Inc. Gives Podium Presentation and Poster at the Society for Immunotherapy of Cancer Annual Meeting

Company Reviews Mechanism of Action, Preclinical Outcomes and Phase 1 Safety Results of VX15 (pepinemab) as Single Agent and In Combination Therapy Against Multiple Cancers ROCHESTER, N.Y., Nov. 15,...
November 13, 2018 07:58 ET | Source: Vaccinex, Inc.

Vaccinex Reports Third Quarter 2018 Financial Results and Provides Corporate Update

Lead candidate pepinemab (VX15) being evaluated in three ongoing clinical trials in cancer and Huntington’s Disease Enrollment in CLASSICAL Lung Cancer trial and Cohort B of the SIGNAL Huntington’s...
November 12, 2018 08:30 ET | Source: Vaccinex, Inc.

Vaccinex, Inc. Presents Overview of the Clinical Development of VX15 (pepinemab) for the Potential Treatment of Huntington’s Disease at the Huntington Study Group’s 2018 Annual Meeting

Presentation and Poster Include Previously Announced Results of Cohort A of SIGNAL Trial ROCHESTER, N.Y., Nov. 12, 2018 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage...
November 06, 2018 08:30 ET | Source: Vaccinex, Inc.

Vaccinex, Inc. to Present Data on Its Semaphorin 4D Monoclonal Antibody Programs at Two Conferences Focused on Cancer Immunotherapy and Huntington’s Disease

ROCHESTER, N.Y., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics to treat...
October 23, 2018 08:30 ET | Source: Vaccinex, Inc.

Vaccinex, Inc. to Participate on a Panel and Meet with Investors at the BTIG Healthcare Conference October 25, 2018

ROCHESTER, N.Y., Oct. 23, 2018 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics to treat...
October 02, 2018 08:30 ET | Source: Vaccinex, Inc.

Vaccinex, Inc. Presents Preliminary Data on Its Anti-Semaphorin 4D Monocolonal Antibody Technology at the Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference

ROCHESTER, N.Y., Oct. 02, 2018 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics to treat...